Proto Labs Inc (PRLB) Drops 5.09% on January 13

Equities Staff |

Proto Labs Inc (PRLB) was one of the Russell 2000's biggest losers for Wednesday January 13 as the stock slid 5.09% to $56.10, a loss of $-3.01 per share. Starting at an opening price of $59.51 a share, the stock traded between $55.55 and $59.63 over the course of the trading day. Volume was 157,590 shares over 1,575 trades, against an average daily volume of 208,020 shares and a total float of 26.16 million.

The losses send Proto Labs Inc down to a market cap of $1.47 billion. In the last year, Proto Labs Inc has traded between $79.95 and $57.30, and its 50-day SMA is currently $64.15 and 200-day SMA is $68.54.

The stock has a P/E Ratio of 34.6.

Proto Labs Inc is a manufacturer of custom parts for prototyping and short-run production. It utilizes computer numerical control (CNC) machining and injection molding to manufacture custom parts.

Proto Labs Inc is based out of Maple Plain, MN and has some 1,077 employees. Its CEO is Victoria M. Holt.

For a complete fundamental analysis analysis of Proto Labs Inc, check out’s Stock Valuation Analysis report for PRLB. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets


Autonomous security robots providing advanced detection capabilities at $7 per hour - aiming to define the future of security. Help #StopTheViolence.

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…